Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07610005 · ClinicalTrials.gov registry record · Phase 1
A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants
A Phase 1 study, sponsored by Immunome.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT07610005 is a Phase 1 study that is actively recruiting participants, run by Immunome. The registered enrollment target is 20 participants.
The verdict
NCT07610005, a Phase 1 study, is actively recruiting participants, sponsored by Immunome.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.
Interventions
- DRUG Varegacestat Reference Formulation
- DRUG Varegacestat Test Formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-05-21 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07610005
The ClinicalTrials.gov registry entry for NCT07610005 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Immunome, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Varegacestat Reference Formulation is the first listed.
NCT07610005 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07610005 about?
NCT07610005 is a clinical study titled "A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy Participants". This is an open-label, randomized, crossover study to evaluate the relative bioavailability (rBA) and bioequivalence (BE) of a test capsule formulation of varegacestat compared to reference capsules formulation under fasting conditions.
What is the current status of trial NCT07610005?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2026-05-21. Estimated completion is 2026-06.
What interventions are being tested in trial NCT07610005?
The interventions under investigation include: Varegacestat Reference Formulation (DRUG), Varegacestat Test Formulation (DRUG).
Who is sponsoring clinical trial NCT07610005?
This trial is sponsored by Immunome, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.